Publications by authors named "M Berglund"
To facilitate the translation of immunotherapies from bench to bedside, predictive preclinical models are essential. We developed the in vivo immuno-oncology Hollow Fiber Assay (HFA) to bridge the gap between simpler cell-based in vitro assays and more complex mouse models for immuno-oncology drug evaluation. The assay involves co-culturing human cancer cell lines or primary patient-derived cancer cells with human immune cells inside semipermeable hollow fibers.
View Article and Find Full Text PDFArticle Synopsis
- Neurodegenerative diseases like Alzheimer's are challenging for patients and healthcare systems, especially in aging populations, with immunotherapies like lecanemab and donanemab facing issues due to limited delivery across the blood-brain barrier (BBB).
- A study evaluated camelid single-domain antibodies (VHHs) combined with human antibodies to improve brain delivery, showing that specific fusion proteins could achieve significant brain concentrations and highlighted the importance of optimal binding to the transferrin receptor (TfR).
- Results from experiments in mouse models demonstrated that these VHH-based fusion proteins could effectively target the brain, potentially overcoming BBB limitations for better therapeutic and diagnostic applications in Alzheimer's disease.
Objective: The incidence of late-onset epilepsy (LOE) is rising, and these patients may use an excess of health care resources. This study aimed to measure pre-/post-diagnostic health care use (HCU) for patients with LOE compared to controls.
Methods: This was an observational open cohort study covering years 1998-2019 using UK population-based linked primary care (Clinical Practice Research Datalink [CPRD]) and hospital (HES) electronic health records.
Background: Bisphenol A (BPA; or 4,4'-isopropylidenediphenol) is an endocrine disrupting chemical. It was widely used in a variety of plastic-based manufactured products for several years. The European Food Safety Authority (EFSA) recently reduced the Tolerable Daily Intake (TDI) for BPA by 20,000 times due to concerns about immune-toxicity.
View Article and Find Full Text PDFObjectives: This study compares hearing outcomes of two prosthesis materials, bone and titanium, used in ossiculoplasty.
Design: This retrospective nationwide registry-based study uses data systematically collected by the Swedish Quality Registry for Ear Surgery (SwedEar).
Setting: The data were obtained from clinics in Sweden that perform ossiculoplasty.